Wave Life Sciences reports positive WVE-006 data in alpha-1 antitrypsin deficiency study

Wave Life Sciences Ltd.

200 mg repeat doses achieved 11.9 µM total AAT and 7.2 µM M-AAT, meeting therapeutic levels
Individual during acute phase response showed 20.6 µM total AAT and 10.3 µM M-AAT, first demonstration of restored physiological production
Single 400 mg dose achieved 12.8 µM total AAT and 5.3 µM M-AAT; monthly dosing supported
GSK holds exclusive global license for WVE-006; Wave eligible for up to $525M milestones plus royalties
Data support monthly or less frequent subcutaneous dosing; 400 mg multidose cohort data expected Q1 2026

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.